LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Home・Akcijų sąrašas・Pulse Biosciences Inc

Pulse Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.36 -2.64

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.36

Max

21.94

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2M -17M
Pardavimai	178K 264K
Pelnas, tenkantis vienai akcijai	-0.257
Pelno marža	-6,603.409
Darbuotojai	116
EBITDA	2M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+36.24% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-179M 958M
Ankstesnė atidarymo kaina	24
Ankstesnė uždarymo kaina	21.36

Naujienos nuotaikos

By Acuity

76%

24%

316 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

16.59 / 17.17 Palaikymas ir pasipriešinimas

Pulse Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-25 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Infosys Agrees to Acquire Stratus

2026-03-25 23:58; UTC

Uždarbis

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

2026-03-25 23:58; UTC

Uždarbis

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

2026-03-25 23:41; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

2026-03-25 23:41; UTC

Uždarbis

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

2026-03-25 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Declines on Possible Technical Correction -- Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

2026-03-25 21:58; UTC

Rinkos pokalbiai

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

2026-03-25 21:37; UTC

Rinkos pokalbiai

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

2026-03-25 21:14; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

2026-03-25 21:13; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

2026-03-25 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

2026-03-25 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-25 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-03-25 20:33; UTC

Įsigijimai, susijungimai, perėmimai

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

2026-03-25 20:31; UTC

Uždarbis

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Akcijų palyginimas

Kainos pokytis

Pulse Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

36.24% į viršų

12 mėnesių prognozė

Vidutinis 30 USD 36.24%

Aukščiausias 30 USD

Žemiausias 30 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pulse Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Pulse Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

16.59 / 17.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

316 / 350 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.